The short-term effects of incremental doses of procainamide (7.5, 15, 22.5, and 30 mg/kg) on right ventricular effective refractory period, intraventricular conduction, and induction of ventricular tachycardia were determined in 31 patients who had a history of sustained, unimorphic ventricular tachycardia. QRS duration during incremental ventricular pacing was used as an index of rate-dependent changes in intraventricular conduction. The mean plasma procainamide concentrations corresponding to the incremental doses were 5.5 1.2 ( + SD), 9.0 + 1.6, 12.6 + 2.2, and 16.3 + 3.2 mg/liter. Each incremental dose of procainamide up to a dose of 30 mg/kg resulted in a significant increment in right ventricular effective refractory period and each dose up to 22.5 mg/kg potentiated a rate-dependent prolongation of QRS duration. After the 7.5 mg/kg dose of procainamide, induction of ventricular tachycardia was suppressed in eight of 31 patients. After higher doses of procainamide, induction of ventricular tachycardia was suppressed in two additional patients. In three of 10 patients in whom the induction of ventricular tachycardia was suppressed by 7.5, 15, or 22.5 mg/kg of procainamide, sustained unimorphic ventricular tachycardia was again inducible after a higher dose of procainamide. In three of 31 patients, only nonsustained ventricular tachycardia was inducible after a 7.5 to 22.5 mg/kg dose of procainamide; however, in two of these three patients, sustained ventricular tachycardia was again inducible after administration of a higher dose of procainamide. In conclusion, during electropharmacologic testing with procainamide, it is worthwhile to test a dose of 7.5 mg/kg, because this dose is often effective in patients who respond to this drug. However, the results of this study indicate that procainamide may be effective in suppressing the induction of sustained ventricular tachycardia at a relatively low plasma concentration, but not at a higher plasma concentration. Therefore, during long-term therapy with procainamide it may be important to avoid plasma procainamide concentrations not only lower, but also higher than the concentration that results in the suppression of induction of tachycardia.
induction of ventricular tachycardia. Therefore, the most appropriate dose(s) of procainamide to administer during electropharmacologic testing has remained undetermined.
In addition to prolonging ventricular refractoriness, procainamide blocks sodium channels in a use-dependent fashion," resulting in rate-dependent slowing of intraventricular conduction.'2 Presumably because of differing relative effects on refractoriness and conduction, different doses of procainamide may have variable effects on the inducibility of ventricular tachycardia.3'4 For example, whereas a small dose of procainamide may facilitate the induction of ventricular tachycardia, a higher dose in the same patient may completely suppress its induction.3 6 However, no prior studies have examined the relative effects of varying doses of procainamide on ventricular refractoriness and conduction.
In prior studies in which incremental doses of procainamide were administered to suppress the induction of ventricular tachycardia, additional doses of procainamide were not tested once the induction was suppressed.4 6 It is therefore unclear whether a higher dose of procainamide may ever facilitate the induction of ventricular tachycardia that is suppressed by a lower dose. This would have important implications for electropharmacologic testing.
The aim of this prospective study was to systematically determine the effects of incremental doses of intravenous procainamide (7.5, 15, 22.5, and 30 mg/kg) on ventricular refractoriness, intraventricular conduction, and induction of ventricular tachycardia. This study was designed to answer the following questions: (1) Is there any value to testing a relatively small dose of procainamide (7.5 mg/kg) during short-term electropharmacologic testing? (2) If a small dose of intravenous procainamide is not effective in suppressing the induction of ventricular tachycardia, what is the yield of testing higher doses of procainamide? (3) Do higher doses of procainamide ever facilitate the induction of ventricular tachycardia that is suppressed by a lower dose? (4) Is there a discernible relationship between the effects of incremental doses of procainamide on ventricular refractoriness and conduction and effects on induction of ventricular tachycardia?
Methods
Patients studied. The subjects in this study were 31 patients with a history of sustained ventricular tachycardia who underwent electrophysiologic testing at the University of Michigan Medical Center and who met the following selection criteria: (1) in the drug-free state, sustained unimorphic ventricular tachycardia of one configuration was reproducibly inducible by programnmed ventricular stimulation and did not require directcurrent countershock for termination, (2) the QRS complex in lead V,, I, or III during ventricular pacing had a well-defined onset and termination, (3) there was not a history of intolerance to or inefficacy of oral procainamide in controlling ventricular tachycardia.
There were 26 men and five women, with a mean age of 62 + 1 1 years (mean + 1 SD). Twenty-six patients had coronary artery disease and a history of a myocardial infarction, two patients had congestive cardiomyopathy, two patients had mitral valve disease, and one patient had undergone aortic valve replacement for treatment of aortic stenosis. The mean left ventricular ejection fraction as determined by either contrast or radionuclide ventriculography was 0.40 + 0. 10 (range 0. 13 to 0.58).
The patients had a history of 2.3 + 2 (range 1 to 4) episodes of sustained ventricular tachycardia. They had undergone 0.9 + 1 (range 0 to 2) unsuccessful drug trials with conventional antiarrhythmic drugs other than procainamide before being re-ferred for electrophysiologic study. A 12-lead electrocardiographic recording of a spontaneous episode of ventricular tachycardia was available for 18 patients. Protocol for programmed ventricular stimulation. After informed consent was obtained, the patients were studied while in the fasting, unsedated state, at least four half-lives after discontinuation of treatment with all antiarrhythmic drugs. Two quadripolar electrode catheters were inserted percutaneously through a femoral vein and positioned against the right ventricular apex and outflow tract. Electrocardiographic leads V,, I, and III, and the intracardiac electrograms recorded at the right ventricular apex and outflow tract were recorded at a paper speed of 25 to 50 mm/sec with an Electronics for Medicine VR-16 or Siemens-Elema Mingograph-7 recorder. Pacing was performed at a current strength of twice diastolic threshold (pulse width 2 msec) with a programmable stimulator (Bloom Associates. LTD). In all patients, the pacing threshold was less than 1 mA.
The programmed ventricular stimulation protocol was performed with two basic drive cycle lengths (600. 550, or 500 msec, and 400 msec). After trains of six to eight stimuli, single then double extrastimuli were introduced at the right ventricular apex, then at the right ventricular outflow tract. If sustained ventricular tachycardia was not induced, programmed stimulation with three extrastimuli was performed at the right ventricular apex, then at the right ventricular outflow tract.
Sustained ventricular tachycardia was defined as that at least 30 sec in duration. Nonsustained ventricular tachycardia was defined as that six complexes to 30 sec in duration.
In each patient, sustained unimorphic ventricular tachycardia was induced with the protocol described above and terminated with overdrive pacing. A 12-lead electrocardiographic recording of the induced ventricular tachycardia was obtained in each patient. Attempts at induction were repeated at least once in all patients to confirm that the same configuration of unimorphic ventricular tachycardia was reproducibly inducible. Patients with polymorphic ventricular tachycardia in the control state were not included in this study.
The right ventricular effective refractory period was determined at the same right ventricular site and at the same basic drive cycle length used to induce ventricular tachycardia.
By a method described previously, the QRS width during pacing at the right ventricular apex was used to assess ratedependent changes in global intraventricular conduction. 12 Trains of 15 to 20 stimuli were introduced at paced cycle lengths of 600, 500, 400, 300, and 250 msec, and the last three to five complexes of each pacing train were recorded at a paper speed of 150 to 200 mm/sec. Protocol for drug testing. The catheters positioned at the right ventricular apex and outflow tract were not moved during drug testing. After completion of the control study, 7.5 mg/kg of intravenous procainamide was administered at a rate of 50 mg/min and a continuous infusion of 2 mg/min was started. Five minutes after administration of the bolus dose, incremental ventricular pacing was repeated at the right ventricular apex, and then programmed ventricular stimulation (including determination of the effective refractory period) was performed at the same right ventricular site and at the same basic drive cycle length used to induce ventricular tachycardia in the control state.
The drug testing protocol was different than the stimulation protocol used in the control state. To assess changes in the number of extrastimuli required to induce ventricular tachycardia at a particular site and basic drive cycle length, single, double, and triple extrastimuli were introduced in sequence at the same site and basic drive cycle length used to induce ventricular tachycardia in the control state. If sustained ventricular tachycardia was not induced, programmed stimulation was then performed at the second basic drive cycle length and at the second right ventricular site.
The end point for programmed ventricular stimulation was the induction of sustained ventricular tachycardia that had the same configuration on a 12-lead electrocardiogram as that induced in the control state or completion of the programmed ventricular stimulation protocol. The only exception was one patient in whom ventricular flutter requiring direct-current countershock was induced by triple extrastimuli at the same site and basic drive cycle length used to induce ventricular tachycardia in the control state; the stimulation protocol was stopped at this point and the next dose of procainamide was administered.
Procainamide was administered in incremental doses of 7.5 mg/kg and the drug testing protocol described above was repeated after a total dose of 15, 22.5, and 30 mg/kg. The infusion rate was 50 mg/min, but if the systolic blood pressure dropped below 100 mm Hg, the infusion rate was slowed to 25 mg/min.
In nine of the 31 patients the administration of 30 mg/kg of procainamide was limited by the occurrence of severe hypotension (systolic blood pressure less than 90 mm Hg), and drug testing at this dose was not performed.
Complete suppression of induction of ventricular tachycardia during drug testing was defined as the inability to induce sustained or nonsustained tachycardia with the complete stimulation protocol. Partial suppression of induction of ventricular tachycardia during drug testing was defined as the ability to induce nonsustained but not sustained ventricular tachycardia with the complete stimulation protocol after the administration of a particular dose of procainamide.
Plasma drug concentrations. The plasma concentrations of procainamide and its principle metabolite, N-acetyl procainamide, were determined by reverse-phase high-performance liquid chromatography.
A blood sample for determination of the plasma procainamide and N-acetyl procainamide concentrations was drawn on completion of the stimulation protocol after each dose of procainamide. In addition, in the last 15 patients studied, the plasma concentrations of procainamide and N-acetyl procainamide were also determined at the onset of programmed stimulation 5 min after the administration of a dose of procainamide.
The duration of the pacing protocol after each dose of procainamide ranged from 5 to 20 min. During this time interval, the plasma procainamide concentration decreased by 1.8 + 0.7 mg/liter (range 0.5 to 2.7) in the 15 patients in whom the concentration was measured before and after pacing.
Data analysis. The duration of the QRS complex during ventricular pacing was measured from the lead that provided the best definition of the onset and termination of the QRS complex. The duration of the last QRS complex of each pacing train was measured. Intraobserver reproducibility was greater than 95%. Data on the QRS duration at a paced cycle length of 250 msec are not included in the results, because in most patients there was not 1: 1 ventricular capture at this paced cycle length after the administration of procainamide.
Statistical analysis was performed by analysis of variance with repeated measures with Fisher's least significant difference multiple comparison technique. Data from patients with and without inducible sustained ventricular tachycardia were compared by use of Student's t test. Patients requiring the same, fewer, or more extrastimuli to induce ventricular tachycardia during drug testing were compared by analysis of variance. Values are expressed as mean + 1 SD.
Results
Procainamide doses and plasma concentrations. The mean procainamide doses equivalent to 7.5, 15, 22.5, Vol. 74, No. 6, December 1986 and 30 mg/kg were 530 + 53, 1060 ± 106, 1590 ± 159, and 2073 ± 162 mg, respectively. The mean plasma concentrations of procainamide corresponding to these incremental doses were 5.5 + 1 .2, 9.0 + 1 .6, 12.6 ± 2.2, and 16.3 ± 3.2 mg/liter (table 1) . Each of these mean procainamide concentrations was significantly greater than the preceding plasma concentration (p < .001).
The mean plasma concentrations of N-acetyl procainamide corresponding to the incremental doses of procainamide were 0.9 ± 0.5, 1.3 + 0.6, 1.6 ± 0.6, and 1.8 ± 0.6 mg/liter.
Right ventricular effective refractory period. In the control state, the mean right ventricular effective refractory period was 225 ± 20 msec. At each incremental dose of procainamide, there was a significant increase in the right ventricular effective refractory period (p < .001 or p < .01; table 1 and figure 1). Rate-dependent QRS prolongation. In the control state, the mean QRS duration was the same at all ventricular paced cycle lengths (table 2). After administration of 7.5 mg/kg of procainamide, there was a rate-dependent increase in QRS duration. At ventricular paced cycle lengths of 600 and 300 msec, there were 15 + 8% and 24 ± 10% increases in QRS duration, respectively (p < .001). The rate-dependent prolongation in QRS duration was potentiated by incremental doses of procainamide, up to a dose of 22.5 mg/kg (table 2 and  figure 2 ). At a dose of 30 mg/kg of procainamide, the QRS duration at paced cycle lengths of 600 and 300 msec was not significantly different than that at a dose of 22.5 mg/kg (p > .05).
Baseline characteristics of induced ventricular tachycardia. In the control state, sustained ventricular tachycardia was induced by one extrastimulus in six patients, by two extrastimuli in 17 patients, and by three extrastimuli in eight patients. The ventricular tachycardia was induced at the right ventricular apex in 26 patients and at the right ventricular outflow tract in five patients. The morphologies of the induced ventricular tachycardias are described in tables 3 and 4. Among the 18 patients in whom a 12-lead electrocardiographic recording of the spontaneous episode of ventricular tachycardia was available, the induced tachycardia had the same configuration as the spontaneous one in 14 patients, and a different configuration in four patients.
Complete suppression of induction of ventricular tachycardia. After administration of 7.5 mg/kg of procainamide, the induction of ventricular tachycardia was suppressed in eight of 31 patients (26%, table 3). Among the 23 patients in whom the induction of ventricular tachycardia was not suppressed by 7.5 mg/kg of pro- cainamide, induction was suppressed by a higher dose in only two patients (9%). In one of these two patients the effective dose of procainamide was 15 mg/kg and in the other it was 22.5 mg/kg (table 3) . Relative effects on refractoriness, conduction, and induction of ventricular tachycardia. In the comparison of the effects of the 7.5 mg/kg dose of procainamide in the eight patients in whom the induction of ventricular tachycardia was completely suppressed by this dose with the 23 patients in whom it was not, it was observed that there was not a significant difference in the degree of prolongation of the right ventricular effective refractoryperiod (10 + 5% vs 11 + 7%, p > .05), the degree of QRS prolongation at a paced cycle length of 600 msec (14 + 4% vs 13 ± 9%, p > .05), or the 1358 degree of QRS prolongation at a paced cycle length of 300 msec (26 + 3% vs 25 ± 10%, p > .05).
Results of oral drug testing after oral procainamide. Patients 1 to 6, in whom the induction of ventricular tachycardia was completely suppressed by 7.5 mg/kg of intravenous procainamide, subsequently underwent repeat testing while being treated with oral procainamide at a daily dose of 2 to 3 g. The plasma procainamide concentration at the time of electropharmacologic testing after oral drug was within 0.5 to 2.1 mg/liter of the plasma concentration measured during testing after intravenous drug. In none of these patients was ventricular tachycardia inducible. not completely suppress the induction of ventricular tachycardia, there was partial suppression of induced tachycardia in one patient after the administration of 7.5 mg/kg of procainamide. Higher doses of procainamide resulted in the partial suppression of induction of ventricular tachycardia in only two additional patients, both at a dose of 15 mg/kg.
Facilitation of induction of ventricular tachycardia.
Among the 10 patients in whom the induction of ventricular tachycardia was completely suppressed by 7.5, 15, or 22.5 mg/kg, sustained tachycardia was again inducible after the administration of a higher dose of procainamide in three patients. In these three patients, the plasma procainamide concentration at which ventricular tachycardia was again inducible exceeded the plasma concentration at which induction was completely suppressed by 3.4, 3.6, and 3.9 mg/liter. The ventricular tachycardia was unimorphic in all three patients and had the same configuration as that induced in the baseline state in two of the three patients.
Among the three patients in whom procainamide partially suppressed the induction of ventricular tachycardia, sustained tachycardia was again inducible in two patients after the administration of a higher dose of procainamide. In these two patients, the plasma procainamide concentrations at which sustained ventricular tachycardia was again inducible were 3.7 and 5.8 mg/liter higher than the plasma concentrations at which induction was partially suppressed. In both patients the induced ventricular tachycardia had the same configuration as that induced in the baseline state.
Vol. 74, No. 6, December 1986 Cycle length of ventricular tachycardia. In the control state, the mean cycle length of induced ventricular tachycardia was 298 + 41 msec. The 7.5 and 15 mg/kg doses of procainamide resulted in significant incremental lengthening of the cycle length of tachycardia in patients in whom ventricular tachycardia was still inducible (to 361 ± 63 msec, p < .001, and 393 ± 71 msec, p < .05, respectively). The mean cycle lengths after doses of 22.5 and 30 mg/kg were not significantly different than those after the 15 and 22.5 mg/kg doses, respectively (p > .05).
Number of extrastimuli required to induce ventricular tachycardia. In 23 patients, ventricular tachycardia was still inducible after administration of 7.5 mg/kg of procainamide. In 13 of these patients there was no change compared with baseline in the number of extrastimuli required to induce ventricular tachycardia; in seven patients the number of extrastimuli required decreased, and in three patients the number of extrastimuli required increased. There were no significant differences in the effects of 7.5 mg/kg of procainamide on right ventricular effective refractory period or QRS duration at a paced cycle length of 600 or 300 msec (table 5) in these three subgroups of patients. Similarly, no significant differences in the effects on refractoriness or conduction were observed after administration of higher doses of procainamide in these three subgroups of patients.
Discussion
Efficacy of 7.5 mg/kg procainamide. In this prospective study of the electrophysiologic effects of incremental doses of procainamide in patients with sustained ventricular tachycardia, a 7.5 mg/kg dose was found to suppress the induction of tachycardia in eight of 10 patients in whom it became noninducible. This result 2 . The rate-dependent effects of incremental doses of procainamide on QRS duration. At each dose of procainamide, the percent change from control in QRS duration was greater at a ventricular paced cycle length of 300 msec than at that of 600 msec. The rate-dependent prolongation in QRS duration was potentiated by each incremental dose of procainamide up to 22.5 mg/kg. suggests that when procainamide is effective in suppressing the induction of ventricular tachycardia during electropharmacologic testing, the dose that is effective may often be as small as 7.5 mg/kg. In the average-size patient, this dose of procainamide is approximately half the size of the dose that traditionally has been used during electropharmacologic testing, namely 1 g or 15 mg/kg.3' 4.6. 9. 10 Therefore, the doses of procainamide that have been used conventionally to suppress the induction of ventricular tachycardia may be higher than necessary in many patients.
In six of six patients in whom the induction of ventricular tachycardia was suppressed by 7.5 mg/kg of intravenous procainamide and in whom electrophysiologic testing was repeated during treatment with oral procainamide, the induction of ventricular tachycardia was suppressed by plasma procainamide concentrations within 0.5 to 2.1 mg/liter of those measured during short-term drug testing. This observation confirms the findings of Marchlinski et al. , who reported that the response to programmed ventricular stimulation was the same after intravenous and oral administration of procainamide whenever the plasma concentrations during intravenous and oral drug testing were within 3 mg/liter of each other. Marchlinski et al.9 concluded that when intravenous procainamide prevents the induction of ventricular tachycardia, repeat electrophysiologic testing during oral administration is not necessary if a similar plasma concentration is achieved. This stresses the importance of testing an initial dose of procainamide of 7.5 mg/kg during electropharmacologic testing instead of the conventionally used dose of 15 mg/kg or 1 g. Control of ventricular tachycardia by the 7.5 mg/kg dose indicates that a smaller oral dose of procainamide can be used for long-term therapy, thereby decreasing the expense and the risk of dose-related adverse drug reactions. Efricacy of 15 to 30 mg/kg procainamide. If a 7.5 mg/kg dose of procainamide is not effective in suppressing the induction of ventricular tachycardia, higher doses appear to be of limited value. Only two of 23 patients in this study (9%) who did not respond to 7.5 mg/kg of procainamide responded to a 15 or 22.5 mg/kg dose, and no additional patients responded to a 30 mg/kg dose. Therefore, if a 7.5 mg/kg dose of procainamide is not effective during electroharnacologic testing, the yield of testing doses up to four times larger is small.
The findings of this study are consistent with the results of a prior study by Engel et al. 6 Among five patients they studied in whom a 500 mg dose of procainamide (approximately 7.5 mg/kg in a 70 kg patient) was not effective in suppressing the induction of ventricular tachycardia, in only one patient was induction suppressed by higher doses of up to 3 g.
Facilitation of induction of ventricular tachycardia by
procainamide. Of note is that in three of 10 patients in whom the induction of sustained ventricular tachycar-Vol. 74, No. 6, December 1986 dia was completely suppressed and in two of three patients in whom the induction of ventricular tachycardia was partially suppressed after a 7.5, 15, or 22.5 mg/kg dose of procainamide, sustained tachycardia was again inducible after administration of a higher dose. In one of these patients, the sustained ventricular tachycardia induced after administration of the higher dose of procainamide had a different morphology than that observed at control. Because the morphology of ventricular tachycardia was different, its clinical significance is unclear. However, in four patients in whom the induction of sustained ventricular tachycar- TABLE 5 Relative elfects on refractoriness, conduction, and the number of extrastimuli required to induce ventricular tachycardia during drug testing with procainamide (7.5 mg/kg) Percent increaseA (mean + SD) dia was completely or partially suppressed, the sustained tachycardia induced after a higher dose of procainamide had the same configuration as that observed at control. Therefore, a smaller dose of procainamide may prevent the induction of ventricular tachycardia, whereas a higher dose of procainamide may facilitate its induction. A prior study of the immediate reproducibility of induction of ventricular tachycardia demonstrated that when a particular form of unimorphic tachycardia was inducible on two consecutive attempts, it was always also inducible on a third attempt. 13 In the present study, ventricular tachycardia was induced in the baseline state on at least two occasions in each patient. It is therefore unlikely that the apparent suppression of induction of tachycardia by a dose of procainamide and its facilitation by a higher dose was related to random nonreproducibility instead of a drug effect.
Because the suppression of induction of ventricular tachycardia at a particular plasma procainamide concentration does not guarantee that higher plasma concentrations will also be effective, during long-term treatment in some patients it may be important to avoid plasma procainamide concentrations that are not only lower, but also higher than those at which induction of ventricular tachycardia was suppressed during electropharmacologic testing.
The plasma procainamide concentrations at which sustained ventricular tachycardia became inducible after initially being suppressed were 3.5 to 5.8 mg/liter higher than those that resulted in suppression of induction of ventricular tachycardia. This may have an important implication regarding treatment with oral procainamide if there is significant fluctuation in the plasma concentration of the drug during the dosing interval. Even with the sustained-release form of procainamide, which minimizes the fluctuation in plasma drug concentrations over the dosing interval compared with the conventional form, the maximal and minimal plasma concentrations may differ by more than 3.4 mg/liter.'4 Giardina et al.14 found that among 22 patients being treated with a sustained-release preparation of procainamide, the peak and trough drug concentrations during an 8 hr dosing interval differed by 3.4 mg/liter or more in 10 patients. Therefore, the results of the present study suggest the possibility that the suppression of inducible ventricular tachycardia during the trough period of the dosing interval in some patients may not exclude the possibility of inducible sustained ventricular tachycardia at times when the plasma procainamide concentration is higher.
Relationship between effects on refractoriness, conduc-1362 tion, and induction of ventricular tachycardia. Procainamide is presumed to suppress or modify ventricular tachycardia by prolonging refractoriness and/or slowing conduction in the reentry circuit responsible for the tachycardia.3' However, in this study no correlation was apparent between the effects of procainamide on induction of ventricular tachycardia and its effects on the right ventricular effective refractory period or QRS duration during ventricular pacing, an index of global ventricular conduction. Whereas a direct relationship existed between the procainamide dose and changes in ventricular refractoriness and QRS duration, there was no such relationship between the dose and its efficacy in preventing the initiation of ventricular tachycardia.
In addition, no difference in the effects of procainamide on right ventricular effective refractory period or QRS duration could be discerned between patients in whom the induction of sustained ventricular tachycardia was completely suppressed and those in whom it was not. Furthermore, although an increase or decrease in the number of extrastimuli required to induce ventricular tachycardia during drug testing is presumably related to different relative effects of procainamide on conduction and refractoriness, no difference in the relative effects of procainamide on right ventricular effective refractory period or QRS duration could be identified in patients who required fewer, more, or the same number of extrastimuli to induce ventricular tachycardia during drug testing.
The most likely explanation for these observations is that changes in the right ventricular effective refractory period and intraventricular conduction (as reflected by changes in QRS duration during ventricular pacing), although indexes of procainamide's global effects on the myocardium, may not accurately reflect the drug's effects on conduction and refractoriness within the reentry circuit responsible for generation of ventricular tachycardia.
Limitations. A limitation of this study is that the subjects consisted of highly selected patients with ventricular tachycardia, and results of drug testing with procainamide in these patients may not be applicable to other types of patients with tachycardia. To avoid the need for repeated direct-current countershocks. patients were included in this study only if their ventricular tachycardia could be terminated by right ventricular pacing. In addition, patients who had multiple morphologies of unimorphic tachycardia in the control state were excluded, because this would have precluded any conclusions regarding the incremental effects of procainamide on a particular type of ventricular tachycardia. These criteria may have selected patients more likely to respond to a relatively low dose of procainamide. However, because the overall incidence of complete suppression of ventricular tachycardia with procainamide in this study (26%) is similar or lower than the response rate found in other studies in unselected patients with tachycardia,3' 6' 9 it is unlikely that there was a strong bias toward inclusion of patients more likely to respond to procainamide.
A second limitation is that changes in the number of extrastimuli required to induce ventricular tachycardia during drug testing may have been random and unrelated to the effects of procainamide. Even when ventricular tachycardia is induced on two consecutive attempts with the same number of extrastimuli, there is an approximately 10% chance that there will be a change in the number of extrastimuli required on a third attempt. 13
Finally, during the 5 to 20 min needed to evaluate the electrophysiologic effects of each dose of procainamide, the plasma concentrations of the drug decreased by 0.5 to 2.7 mg/liter. A continuous infusion of 2 mg/min of procainamide was used to minimize the change in plasma procainamide concentration during the stimulation protocol, but it is clear that a steadystate concentration was not reached. However, although the drug administration protocol was not ideal from a pharmacokinetic standpoint, many clinical electrophysiology laboratories base decisions on a similar protocol. Furthermore, the results of programmed ventricular stimulation after the intravenous administration of 7.5 mg/kg of procainamide were concordant with the results obtained at similar plasma concentrations during long-term oral therapy.
In conclusion, from a therapeutic viewpoint, the optimal goal of electropharmacologic testing with a drug such as procainamide is to identify the lowest dose that suppresses the induction of ventricular tachycardia. However, to do so may require a time-consuming process of testing multiple small increments in dosage. Patient tolerance to this process is likely to be poor, especially if ventricular tachycardia is induced on multiple occasions. An appropriate compromise between the need to avoid a lengthy and uncomfortable study and the desirability of identifying the minimum effective dose of procainamide during short-term electropharmacologic testing may be to initially test a 7.5 mg/kg dose of procainamide, and if this is not effective, to then test a dose of 15 or 22.5 mg/kg. If these doses are not effective, the yield of a 30 mg/kg dose is likely to be so low that the additional time required to test this dose is not warranted.
A limitation of electropharmacologic testing in the Vol. 74, No. 6, December 1986 assessment of the efficacy of oral antiarrhythmic drugs in suppressing the induction of ventricular tachycardia is that it is not feasible to evaluate the efficacy of the full range of plasma drug concentrations that may occur during the dosing interval. Patients are therefore usually tested when the plasma drug concentration is at its lowest during the dosing interval. However, the results of this study suggest that, at least in some patients, efficacy of an antiarrhythmic drug such as procainamide in suppressing the induction of ventricular tachycardia when the plasma drug concentration is at its minimum level may not guarantee efficacy at times during the dosing interval when the plasma drug concentration is higher. Additional studies in which electrophysiologic testing is performed at various times during the dosing interval in patients being treated with oral antiarrhythmic drugs are needed to evaluate this possibility and its implications regarding the suppression of spontaneous episodes of ventricular tachycardia. 
